Literature DB >> 21509907

Concise review: Emerging concepts in clinical targeting of cancer stem cells.

Zeshaan A Rasheed1, Jeanne Kowalski, B Douglas Smith, William Matsui.   

Abstract

Cancer stem cells (CSCs) are functionally defined by their ability to self-renew and recapitulate tumors in the ectopic setting. They have been identified in a growing number of human malignancies and their association with poor clinical outcomes has suggested that they are the major factors in dictating clinical outcomes. Moreover, recent studies have demonstrated that CSCs may display other functional attributes, such as drug resistance and invasion and migration, that implicate a broad role in clinical oncology spanning initial tumor formation, relapse following treatment, and disease progression. Although our knowledge regarding the basic biology of CSCs continues to improve, proof that they are clinically relevant is still lacking, and translation of the CSC hypothesis from the laboratory to the clinic is of paramount importance. We will review current evidence supporting the role of CSCs in clinical oncology and discuss potential barriers and strategies in designing trials examining CSC-targeting agents.
Copyright © 2011 AlphaMed Press.

Entities:  

Mesh:

Year:  2011        PMID: 21509907      PMCID: PMC3355871          DOI: 10.1002/stem.648

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  54 in total

1.  Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

Authors:  Philippe Rousselot; Francoise Huguet; Delphine Rea; Laurence Legros; Jean Michel Cayuela; Odile Maarek; Odile Blanchet; Gerald Marit; Eliane Gluckman; Josy Reiffers; Martine Gardembas; François-Xavier Mahon
Journal:  Blood       Date:  2006-09-14       Impact factor: 22.113

2.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Authors:  Charles E Geyer; John Forster; Deborah Lindquist; Stephen Chan; C Gilles Romieu; Tadeusz Pienkowski; Agnieszka Jagiello-Gruszfeld; John Crown; Arlene Chan; Bella Kaufman; Dimosthenis Skarlos; Mario Campone; Neville Davidson; Mark Berger; Cristina Oliva; Stephen D Rubin; Steven Stein; David Cameron
Journal:  N Engl J Med       Date:  2006-12-28       Impact factor: 91.245

Review 3.  High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials.

Authors:  John Koreth; Corey S Cutler; Benjamin Djulbegovic; Rajesh Behl; Robert L Schlossman; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson; Robert J Soiffer; Edwin P Alyea
Journal:  Biol Blood Marrow Transplant       Date:  2007-02       Impact factor: 5.742

4.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Authors:  Brian J Druker; François Guilhot; Stephen G O'Brien; Insa Gathmann; Hagop Kantarjian; Norbert Gattermann; Michael W N Deininger; Richard T Silver; John M Goldman; Richard M Stone; Francisco Cervantes; Andreas Hochhaus; Bayard L Powell; Janice L Gabrilove; Philippe Rousselot; Josy Reiffers; Jan J Cornelissen; Timothy Hughes; Hermine Agis; Thomas Fischer; Gregor Verhoef; John Shepherd; Giuseppe Saglio; Alois Gratwohl; Johan L Nielsen; Jerald P Radich; Bengt Simonsson; Kerry Taylor; Michele Baccarani; Charlene So; Laurie Letvak; Richard A Larson
Journal:  N Engl J Med       Date:  2006-12-07       Impact factor: 91.245

5.  Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  Malcolm J Moore; David Goldstein; John Hamm; Arie Figer; Joel R Hecht; Steven Gallinger; Heather J Au; Pawel Murawa; David Walde; Robert A Wolff; Daniel Campos; Robert Lim; Keyue Ding; Gary Clark; Theodora Voskoglou-Nomikos; Mieke Ptasynski; Wendy Parulekar
Journal:  J Clin Oncol       Date:  2007-04-23       Impact factor: 44.544

6.  Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.

Authors:  William Matsui; Qiuju Wang; James P Barber; Sarah Brennan; B Douglas Smith; Ivan Borrello; Ian McNiece; Lan Lin; Richard F Ambinder; Craig Peacock; D Neil Watkins; Carol Ann Huff; Richard J Jones
Journal:  Cancer Res       Date:  2008-01-01       Impact factor: 12.701

7.  Stem cell marker CD133 affects clinical outcome in glioma patients.

Authors:  Felix Zeppernick; Rezvan Ahmadi; Benito Campos; Christine Dictus; Burkhard M Helmke; Natalia Becker; Peter Lichter; Andreas Unterberg; Bernhard Radlwimmer; Christel C Herold-Mende
Journal:  Clin Cancer Res       Date:  2008-01-01       Impact factor: 12.531

8.  Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma.

Authors:  Craig D Peacock; Qiuju Wang; Gregory S Gesell; Ian M Corcoran-Schwartz; Evan Jones; Jynho Kim; Wendy L Devereux; Jonathan T Rhodes; Carol A Huff; Philip A Beachy; D Neil Watkins; William Matsui
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-27       Impact factor: 11.205

9.  Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma.

Authors:  Eli E Bar; Aneeka Chaudhry; Alex Lin; Xing Fan; Karisa Schreck; William Matsui; Sara Piccirillo; Angelo L Vescovi; Francesco DiMeco; Alessandro Olivi; Charles G Eberhart
Journal:  Stem Cells       Date:  2007-07-12       Impact factor: 6.277

10.  Molecular definition of breast tumor heterogeneity.

Authors:  Michail Shipitsin; Lauren L Campbell; Pedram Argani; Stanislawa Weremowicz; Noga Bloushtain-Qimron; Jun Yao; Tatiana Nikolskaya; Tatiana Serebryiskaya; Rameen Beroukhim; Min Hu; Marc K Halushka; Saraswati Sukumar; Leroy M Parker; Karen S Anderson; Lyndsay N Harris; Judy E Garber; Andrea L Richardson; Stuart J Schnitt; Yuri Nikolsky; Rebecca S Gelman; Kornelia Polyak
Journal:  Cancer Cell       Date:  2007-03       Impact factor: 31.743

View more
  42 in total

1.  Perspective: A model disease.

Authors:  William Matsui
Journal:  Nature       Date:  2011-12-14       Impact factor: 49.962

Review 2.  Cancer stem cells: involvement in pancreatic cancer pathogenesis and perspectives on cancer therapeutics.

Authors:  Cristiana Pistol Tanase; Ana Iulia Neagu; Laura Georgiana Necula; Cristina Mambet; Ana-Maria Enciu; Bogdan Calenic; Maria Linda Cruceru; Radu Albulescu
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 3.  Novel therapeutic targets for pancreatic cancer.

Authors:  Shing-Chun Tang; Yang-Chao Chen
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

4.  EGFR blockade enriches for lung cancer stem-like cells through Notch3-dependent signaling.

Authors:  Rajeswara Rao Arasada; Joseph M Amann; Mohammad A Rahman; Stacey S Huppert; David P Carbone
Journal:  Cancer Res       Date:  2014-08-14       Impact factor: 12.701

Review 5.  Therapeutic resistance and cancer recurrence mechanisms: Unfolding the story of tumour coming back.

Authors:  Mohammad Javad Dehghan Esmatabadi; Babak Bakhshinejad; Fatemeh Movahedi Motlagh; Sadegh Babashah; Majid Sadeghizadeh
Journal:  J Biosci       Date:  2016-09       Impact factor: 1.826

Review 6.  Melanoma tumor cell heterogeneity: a molecular approach to study subpopulations expressing the embryonic morphogen nodal.

Authors:  Elisabeth A Seftor; Richard E B Seftor; Don Weldon; Gina T Kirsammer; Naira V Margaryan; Alina Gilgur; Mary J C Hendrix
Journal:  Semin Oncol       Date:  2014-02-07       Impact factor: 4.929

Review 7.  Lung cancer stem cells: a biological and clinical perspective.

Authors:  Ana Koren; Helena Motaln; Tanja Cufer
Journal:  Cell Oncol (Dordr)       Date:  2013-07-31       Impact factor: 6.730

8.  Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis.

Authors:  Yasmine Touil; Wassila Igoudjil; Matthieu Corvaisier; Anne-Frédérique Dessein; Jérôme Vandomme; Didier Monté; Laurence Stechly; Nicolas Skrypek; Carole Langlois; Georges Grard; Guillaume Millet; Emmanuelle Leteurtre; Patrick Dumont; Stéphanie Truant; François-René Pruvot; Mohamed Hebbar; Fan Fan; Lee M Ellis; Pierre Formstecher; Isabelle Van Seuningen; Christian Gespach; Renata Polakowska; Guillemette Huet
Journal:  Clin Cancer Res       Date:  2013-12-09       Impact factor: 12.531

9.  ALDH enzymatic activity and CD133 positivity and response to chemotherapy in ovarian cancer patients.

Authors:  Francesca Ricci; Sergio Bernasconi; Luca Porcu; Eugenio Erba; Nicolò Panini; Robert Fruscio; Federica Sina; Valter Torri; Massimo Broggini; Giovanna Damia
Journal:  Am J Cancer Res       Date:  2013-04-03       Impact factor: 6.166

10.  New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells.

Authors:  Soo Ok Lee; Zhifang Ma; Chiuan-Ren Yeh; Jie Luo; Tzu-Hua Lin; Kuo-Pao Lai; Shinichi Yamashita; Liang Liang; Jing Tian; Lei Li; Qi Jiang; Chiung-Kuei Huang; Yuanjie Niu; Shuyuan Yeh; Chawnshang Chang
Journal:  J Mol Cell Biol       Date:  2012-07-24       Impact factor: 6.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.